

- in disability-free early multiple sclerosis. *Behav Neurol* 2003; 14(1–2): 39–45.
28. Camp SJ, Stevenson VL, Thompson AJ, Miller DH, Borrás C, Auriacombe S et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. *Brain* 1999; 122(7): 1341–1348.
29. De Sonneville LM, Boringa JB, Reuling IE, Lazeron RH, Adèr HJ, Polman CH. Information processing characteristics in subtypes of multiple sclerosis. *Neuropsychologia* 2002; 40(11): 1751–1755.
30. Bruce JM, Bruce AS, Arnett PA. Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. *J Int Neuropsychol Soc* 2007; 13(3): 544–548.
31. Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2003; 74(4): 443–446.
32. Henry JD, Beatty WW. Verbal fluency deficits in multiple sclerosis. *Neuropsychologia* 2006; 44(7): 1166–1174.
33. Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. *Arch Neurol* 2007; 64(8): 1157–1161.
34. Dusankova JB, Kalincik T, Havrdova E, Benedict RH. Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). *Clin Neuropsychol* 2012; 26(7): 1186–1200.
35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12(3): 189–198.
36. Mathuranath PS, Cherian JP, Mathew R, George A, Alexander A, Sarma SP. Mini mental state examination and the Addenbrooke's cognitive examination: effect of education and norms for a multicultural population. *Neurol India* 2007; 55(2): 106–110.
37. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53(4): 695–699.
38. Hummelová-Fanfrdlová Z, Rektorová I, Sheardová K, Bartoš A, Línek V, Rössner P et al. Česká adaptace Addenbrookského kognitivního testu (Addenbrooke's Cognitive Examination). *Československá psychologie* 2009; 53(4): 376–388.
39. Sánchez MP, Nieto A, Barroso J, Martín V, Hernández MA. Brain atrophy as a marker of cognitive impairment in mildly disabling relapsing-remitting multiple sclerosis. *Eur J Neurol* 2008; 15(10): 1091–1099.
40. Tekok-Kilic A, Benedict RH, Weinstock-Guttman B, Dwyer MG, Carone D, Srinivasaraghavan B et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. *Neuroimage* 2007; 36(4): 1294–1300.
41. Reuter F, Zaarouï W, Crespy L, Faivre A, Rico A, Malikova I et al. Cognitive impairment at the onset of multiple sclerosis: relationship to lesion location. *Mult Scler* 2011; 17(6): 755–758.
42. Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. *Ann Neurol* 2010; 67(3): 376–383.
43. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. *Arch Neurol* 2009; 66(9): 1144–1150.
44. Obhlidalová I, Keřkovský M, Štourač P, Bednařík P, Vlčková E. Diagnostické možnosti zobrazovacích metod v hodnocení morfologického korelátu kognitivních změn u pacientů s roztroušenou sklerózou. *Cesk Slov Neurol N* 2012; 75/108(2): 170–178.
45. Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, Guidi L et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. *Neurology* 2004; 63(1): 89–93.
46. Benedict RH, Zivadinov R, Carone DA, Weinstock-Guttman B, Gaines J, Maggiore C et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. *AJNR Am J Neuroradiol*. 2005; 26(7): 1824–1831.
47. Houtchens MK, Benedict RH, Killiany R, Sharma J, Jaisani Z, Singh B et al. Thalamic atrophy and cognition in multiple sclerosis. *Neurology* 2007; 69(12): 1213–1223.
48. Lin F, Yu C, Liu Y, Li K, Lei H. Diffusion tensor group tractography of the corpus callosum in clinically isolated syndrome. *AJNR Am J Neuroradiol* 2011; 32(1): 92–98.
49. Rimkus C de M, Junqueira T de F, Lyra KP, Jankowski MP, Machado MA, Miotto EC et al. Corpus callosum microstructural changes correlate with cognitive dysfunction in early stages of relapsing-remitting multiple sclerosis: axial and radial diffusivities approach. *Mult Scler Int* 2011; 2011: 304875.
50. Kalincik T, Vaneckova M, Tyblova M, Krasensky J, Seidl Z, Havrdova E et al. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. *PLoS One* 2012; 7(11): e50101.
51. Vaneckova M, Kalincik T, Krasensky J, Horakova D, Havrdova E, Hrebikova T et al. Corpus callosum atrophy – a simple predictor of multiple sclerosis progression: a longitudinal 9-year study. *Eur Neurol* 2012; 68(1): 23–27.
52. Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. *J Neurol Sci* 2006; 245(1–2): 63–66.
53. Haase CG, Tinnefeld M, Lienemann M, Ganz RE, Faustmann PM. Depression and cognitive impairment in disability-free early multiple sclerosis. *Behav Neurol* 2003; 14(1–2): 39–45.
54. Anhoque CF, Domingues SC, Carvalho T, Teixeira AL, Domingues RB. Anxiety and depressive symptoms in clinically isolated syndrome and multiple sclerosis. *Arq Neuropsiquiatr* 2011; 69(6): 882–886.
55. Zajicek JP, Ingram WM, Vickery J, Creanor S, Wright DE, Hobart JC. Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS). 1: Protocol and baseline characteristics of cohort. *BMC Neurol* 2010; 10: 88.
56. Honarmand K, Akbar N, Kou N, Feinstein A. Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite. *J Neurol* 2011; 258 (2): 244–249.
57. Schultheis MT, Weisser V, Ang J, Elovic E, Nead R, Sestito N. Examining the relationship between cognition and driving performance in multiple sclerosis. *Arch Phys Med Rehabil* 2010; 91(3): 465–473.
58. Leo GJ, Rao SM. Effects of intravenous physostigmine and lecithin on memory loss in multiple sclerosis: Report of a pilot study. *J Neurol Rehabil* 1988; 2: 123–129.
59. Johnson SK, Diamond BJ, Rausch S, Kaufman M, Shiflett SC, Graves L. The effect of Gingko biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial. *Explore* 2006; 2(1): 19–24.
60. Zakzanis KK. Distinct neurocognitive profiles in multiple sclerosis subtypes. *Arch Clin Neuropsychol* 2000; 15(2): 115–136.

Vážené kolegyně a kolegové,

s potěšením Vám oznamujeme, že ve dnech **17.–19. dubna 2014** se v Psychiatrické nemocnici Jihlava bude konat tradiční sympozium biologické psychiatrie s názvem „**Psychiatrie v čase a čas v psychiatrii**“. Bude zaměřeno na chronobiologii a epigenetiku ve vztahu k duševním poruchám, přednesena budou pouze vyžádaná sdělení. Příhlášku máte k dispozici ve svých počítačích na stránce <http://psych.lf1.cuni.cz/sbp/default.htm> v sekci Aktuality.

Na Vaši účast se těší

*Výbor Společnosti pro biologickou psychiatrii  
Výbor Sekce biologické psychiatrie PS ČLS JEP*